Abstract
Objective
Treatment options for refractory overactive bladder (OAB) following behavioral modifications and oral OAB medications remain limited. Up to 33% of women fail botulinum toxin injections (Amundsen et al. Eur Urol. 74(1):66–73, 7). This study evaluates the effectiveness of combining oral OAB agents with botulinum toxin in subjects who failed botulinum toxin therapy alone.
Methods
This is a retrospective observational study. Eligible women were those who received botulinum toxin injections for OAB between 2013 and 2018 at one academic institution. Women were given the option of oral medications as add-back therapy following failed treatment with botulinum toxin alone. Treatment response was a subjective outcome, with subjects reporting being satisfied or unsatisfied. The primary outcome was the proportion of subjects who achieved satisfactory treatment response with the combination of oral OAB medications and botulinum toxin injections. A subanalysis was performed to further investigate any risk factors associated with poor response to combination treatment. Variables were analyzed using chi-squared or Fisher’s exact test and Student's t-test or Mann-Whitney U when appropriate.
Results
A total of 107 charts were reviewed. Forty-five (48%) women failed botulinum toxin alone as a treatment; 26 (29%) elected to try one or more oral OAB medications. Of the 26 women who received the combination treatment, 17 (65%) reported satisfaction and 9 (35%) remained unsatisfied. Risk factors associated with treatment failure were not identified.
Conclusion
This is an initial report on adding back oral OAB meds to patients who have failed botulinum toxin injections suggesting there may be a role for add-back oral OAB medications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kirby A, Park S, et al. Practice patterns for women with overactive bladder syndrome: time between medications and third-line treatments. Female Pelvic Med Reconstr Surg. 2020;26(7):431–6.
Robinson D, Giarenis I, Cardozo L. The management of overactive bladder refractory to medical therapy. Maturitas. 2013;75(1):101–4. https://doi.org/10.1016/j.maturitas.2013.01.013.
AUA/SUFU Guideline: Published 2012; Amended 2014, 2019 Endorsed by the American Urogynecologic Society (AUGS) https://www.auanet.org/guidelines/overactive-bladder-(oab)-guideline. Accessed Oct 2020
White N, Iglesia CB. Overactive bladder. Obstet Gynecol Clin N Am. 2016;43(1):59–68.
Raju R, Linder BJ. Evaluation and treatment of overactive bladder in women. Mayo Clin Proc. 2020;95(2):370–7.
Linder BJ, Gebhart JB, Elliott DS, Van Houten HK, Sangaralingham LR, Habermann EB. National patterns of filled prescriptions and third-line treatment utilization for privately insured women with overactive bladder. Female Pelvic Med Reconstr Surg. https://doi.org/10.1097/SPV.0000000000000744.
Amundsen CL, Komesu YM, Chermansky C, et al. Two-year outcomes of sacral neuromodulation versus OnabotulinumtoxinA for refractory urgency urinary incontinence: a randomized trial. Eur Urol. 2018;74(1):66–73.
Tutolo M, Ammirati E, Heesakkers J, et al. Efficacy and safety of sacral and percutaneous Tibial neuromodulation in non-neurogenic lower urinary tract dysfunction and chronic pelvic pain: a systematic review of the literature. Eur Urol. 2018;73(3):406–18.
Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–22.
Elbaset M, Taha, DE, El-Hefnawy AS, Zahran MH, & Shokeir A, et al. Assessment of anticholinergic use after fading of BTX-A effects in refractory idiopathic overactive bladder: A prospective blinded randomized trial. Int Neurourol J. 2019;23(3):240–248. (Korean Continence Society).
Tang DH, Colayco DC, Khalaf KM, Piercy J, Patel V, Globe D, et al. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder. BJUI. 2014;113(3):484–91.
Vrijens D, Drossaerts J, van Koeveringe G, Van Kerrebroeck P, van Os J, Leue C. Affective symptoms and the overactive bladder - a systematic review. J Psychosom Res. 2015;78(2):95–108.
Moskowitz D, Adelstein SA, Lucioni A, Lee UJ, Kobashi KC. Use of third line therapy for Overactive Bladder in a practice with multiple subspecialty providers-are we doing enough? J Urol. 2018;199(3):779–84.
Author information
Authors and Affiliations
Contributions
Abbigail Woll: Data management, project development, data analysis, manuscript writing/editing.
Steven Swift: Project development, data analysis, manuscript editing.
Autumn Edenfield: Project development, data analysis, manuscript editing.
Mallory Locke: Data management.
Corresponding author
Ethics declarations
Conflicts of interest
None.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Woll, A., Edenfield, A., Locke, M. et al. Treatment outcomes of overactive bladder with combined therapies of botulinum toxin injections and oral agents. Int Urogynecol J 32, 2803–2806 (2021). https://doi.org/10.1007/s00192-021-04676-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00192-021-04676-3